The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani responded to new efforts unveiled today by the Administration to combat Alzheimer’s Disease:
“Alzheimer’s disease is one of America’s top health challenges. It ravages the minds of patients, seriously impacts entire families and currently costs the U.S. health care system $172 billion a year. According to the Alzheimer’s Association, an American will develop the disease every 33 seconds in 2050, costing the U.S. health care system $1.1 trillion. These costs are simply unsustainable,” said John J. Castellani, President and CEO, PhRMA.
“The outlook could change course, however, if a treatment were discovered that helps delay the onset of Alzheimer’s. Biopharmaceutical research companies, recognizing the great health and economic need to help delay or prevent the onset of Alzheimer’s, have invested heavily in this area and are currently researching and developing nearly 100 medicines to help address this public health priority.”
“Discovering an Alzheimer’s treatment is by no means an easy task; and it can certainly benefit from collaborations between industry, academia and federal research institutions. In addition to their individual efforts to discover and develop novel treatments for Alzheimer’s, biopharmaceutical companies have partnered with each other and with academic and federal research institutions to help move forward the scientific understanding of this complex disease,” said Castellani.
“One remarkable example is provided by the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a large five year research project to define the rate of progress of Alzheimer’s disease, develop improved methods for clinical trials in this area, and to provide a large database which may improve development of innovative treatments.”
“We look forward to continuing our engagement with the different stakeholders and constituents involved in this national charge to combat Alzheimer’s,” said Castellani.